Company Profile
Brainstorm Cell Therapeutics Inc. Stock Price, News & Catalysts
- Ticker:
- BCLI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
1.09 USD (+9.64%)
Close
Last updated: August 17, 2026
—
Market cap
Why the stock is moving
Following the latest company update, “BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update”, BCLI closed up 9.64% at $1.09 on Aug 17, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Autologous Cell-Therapy Developer
BrainStorm Cell Therapeutics is developing autologous cellular therapies for neurodegenerative diseases. Its programs use a patient's own cells to deliver neuroprotective and immunomodulatory factors in disorders characterized by progressive neuronal damage.
NurOwn Technology
NurOwn, also known as MSC-NTF, is manufactured from mesenchymal stem cells collected from a patient's bone marrow. The cells are expanded and differentiated outside the body to secrete neurotrophic factors intended to support neuronal survival and modulate neuroinflammation before being administered back to the patient.
ALS Development Program
Amyotrophic lateral sclerosis is the lead indication for NurOwn. The candidate has received orphan-drug designation in the United States and European Union and has completed a Phase 3 study that informed the design of a new confirmatory program.
ENDURANCE Phase 3b Study
ENDURANCE is a planned approximately 200-patient Phase 3b trial operating under an FDA Special Protocol Assessment. It includes a 24-week randomized, placebo-controlled portion followed by a 24-week open-label portion, with change in ALS Functional Rating Scale-Revised score serving as the primary endpoint for the controlled stage.
Broader Regenerative Pipeline
BrainStorm has also completed a Phase 2 study of NurOwn in progressive multiple sclerosis. Beyond its autologous cell program, the company is exploring an allogeneic exosome platform as a potential delivery system for therapeutic proteins and nucleic acids.
Future catalysts
- Initiation of enrollment in the Phase 3b ENDURANCE trial of NurOwn in ALS.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Brainstorm Cell Therapeutics Inc. (BCLI)?
Brainstorm Cell Therapeutics Inc. (BCLI) most recently closed at 1.09 USD, a +9.64% move versus the previous session.
What does Brainstorm Cell Therapeutics Inc. do?
Autologous Cell-Therapy Developer BrainStorm Cell Therapeutics is developing autologous cellular therapies for neurodegenerative diseases. Its programs use a patient's own cells to deliver neuroprotective and immunomodulatory factors in disorders characterized by progressive neuronal damage. NurOwn Technology NurOwn, also known as MSC-NTF, is manufactured...
On which exchange is BCLI stock listed?
Brainstorm Cell Therapeutics Inc. (BCLI) is associated with NASDAQ, Israel, Biopharma.
What is MSC-NTF?
NurOwn Technology NurOwn, also known as MSC-NTF, is manufactured from mesenchymal stem cells collected from a patient's bone marrow.
Which conditions is Brainstorm Cell Therapeutics Inc. targeting with MSC-NTF?
Brainstorm Cell Therapeutics Inc. is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Brainstorm Cell Therapeutics Inc. describe recent progress with MSC-NTF?
Initiation of enrollment in the Phase 3b ENDURANCE trial of NurOwn in ALS.
What is Autologous?
Autologous Cell-Therapy Developer BrainStorm Cell Therapeutics is developing autologous cellular therapies for neurodegenerative diseases.
What should investors watch for with Autologous?
Initiation of enrollment in the Phase 3b ENDURANCE trial of NurOwn in ALS.